<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Vascular safety issues in CML patients treated with BCR/ABL1 kinase inhibitors</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
				<date type="published" when="2022-05-17">17 May 2022</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><forename type="first">Peter</forename><surname>Valent</surname></persName>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Department of Internal Medicine I</orgName>
								<orgName type="department" key="dep2">Division of Hematology &amp; Hemostaseology</orgName>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="department">Ludwig Boltzmann Cluster Oncology</orgName>
								<orgName type="institution">Medical University of Vienna</orgName>
								<address>
									<settlement>Vienna</settlement>
									<country key="AT">Austria</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Emir</forename><surname>Hadzijusufovic</surname></persName>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Department of Internal Medicine I</orgName>
								<orgName type="department" key="dep2">Division of Hematology &amp; Hemostaseology</orgName>
							</affiliation>
							<affiliation key="aff2">
								<orgName type="department" key="dep1">Department/Clinic for Companion Animals and Horses</orgName>
								<orgName type="department" key="dep2">Clinic for Small Animals</orgName>
								<orgName type="department" key="dep3">Clinical Unit of Internal Medicine</orgName>
								<orgName type="institution">University of Veterinary Medicine Vienna</orgName>
								<address>
									<settlement>Vienna</settlement>
									<country key="AT">Austria</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Gerit-Holger</forename><surname>Schernthaner</surname></persName>
							<affiliation key="aff3">
								<orgName type="department" key="dep1">Department of Internal Medicine II</orgName>
								<orgName type="department" key="dep2">Division of Angiology</orgName>
								<orgName type="institution">Medical University of Vienna</orgName>
								<address>
									<settlement>Vienna</settlement>
									<country key="AT">Austria</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Dominik</forename><surname>Wolf</surname></persName>
							<affiliation key="aff4">
								<orgName type="department">Medical Clinic III for Oncology, Haematology and Rheumatology</orgName>
								<orgName type="institution">University Hospital Bonn (UKB)</orgName>
								<address>
									<settlement>Bonn</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Delphine</forename><surname>Rea</surname></persName>
							<affiliation key="aff5">
								<orgName type="department">Service d&apos;H ématologie Adulte</orgName>
								<orgName type="institution">H ôpital Saint-Louis</orgName>
								<address>
									<settlement>Paris</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Philipp</forename><surname>Le Coutre</surname></persName>
							<affiliation key="aff6">
								<orgName type="department">Medical Clinic for Hematology and Oncology</orgName>
								<orgName type="institution">Medical University of Berlin</orgName>
								<address>
									<addrLine>Campus Virchow, Charit é</addrLine>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Vascular safety issues in CML patients treated with BCR/ABL1 kinase inhibitors</title>
					</analytic>
					<monogr>
						<imprint>
							<date type="published" when="2022-05-17">17 May 2022</date>
						</imprint>
					</monogr>
					<idno type="MD5">9F6E45510A8A46B9E9187F854D57BAB3</idno>
					<idno type="DOI">10.1182/blood-</idno>
					<note type="submission">Submitted September 13, 2014; accepted December 7, 2014. Prepublished online as Blood First Edition paper, December 18, 2014;</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:39+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Vascular safety is an emerging issue in patients with chronic myeloid leukemia (CML) treated with tyrosine kinase inhibitors (TKIs).</s><s>Whereas imatinib exhibits a well-documented and favorable long-term safety profile without obvious accumulation of vascular events, several types of vascular adverse events (VAEs) have been described in patients receiving secondor third-generation BCR/ABL1 TKIs.</s><s>Such VAEs include pulmonary hypertension in patients treated with dasatinib, peripheral arterial occlusive disease and other arterial disorders in patients receiving nilotinib, and venous and arterial vascular occlusive events during ponatinib.</s><s>Although each TKI interacts with a unique profile of molecular targets and has been associated with a unique pattern of adverse events, the mechanisms of drug-induced vasculopathy are not well understood.</s><s>Here, recent data and concepts around VAEs in TKI-treated patients with CML are discussed, with special reference to potential mechanisms, event management, and strategies aimed at avoiding occurrence of such events in long-term treated patients.</s><s>(Blood.</s><s>2015;125(6):901-906)</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Introduction</head><p><s>Chronic myeloid leukemia (CML) is characterized by uncontrolled expansion of myeloid cells and the BCR/ABL1 oncogene. <ref type="bibr" target="#b0">1,</ref><ref type="bibr" target="#b1">2</ref></s><s>6]<ref type="bibr" target="#b6">[7]</ref> Treatment of TKI-resistant CML is an emerging challenge.</s><s>2]<ref type="bibr" target="#b22">[23]</ref><ref type="bibr" target="#b23">[24]</ref><ref type="bibr" target="#b24">[25]</ref> However, several targets are also expressed in nonhematopoietic cells and may therefore be responsible for nonhematologic adverse events (AEs).</s><s><ref type="bibr" target="#b30">[31]</ref><ref type="bibr" target="#b31">[32]</ref> The unique profiles of AEs seen with BCR/ABL1 TKIs A unique spectrum of AEs has been reported for each TKI used to treat CML (supplemental Table <ref type="table" target="#tab_0">1</ref>, available on the Blood Web site).</s><s>7]<ref type="bibr" target="#b27">[28]</ref> Several other nonhematologic AEs have also been described for dasatinib. <ref type="bibr" target="#b12">13,</ref><ref type="bibr" target="#b26">27,</ref><ref type="bibr" target="#b32">33</ref></s><s>he frequency of AEs is lower in patients receiving 100 mg of dasatinib once daily compared with higher doses. <ref type="bibr" target="#b27">28,</ref><ref type="bibr" target="#b33">34,</ref><ref type="bibr" target="#b34">35</ref></s><s>However, even at 100 mg per day, pleural effusions may develop. <ref type="bibr" target="#b27">28,</ref><ref type="bibr" target="#b35">36</ref></s><s>8]<ref type="bibr" target="#b38">[39]</ref> However, the frequency of this AE is low <ref type="bibr" target="#b36">[37]</ref><ref type="bibr" target="#b37">[38]</ref><ref type="bibr" target="#b38">[39]</ref> and the same holds true for arterial occlusive events, although VAEs have been reported (supplemental Table <ref type="table" target="#tab_0">1</ref>). <ref type="bibr" target="#b39">40</ref></s><s>ilotinib-treated patients may develop elevated pancreatic enzymes, an increase in serum bilirubin, and/or an increase in fasting glucose levels. <ref type="bibr" target="#b11">12,</ref><ref type="bibr" target="#b16">17,</ref><ref type="bibr" target="#b28">29,</ref><ref type="bibr" target="#b40">41</ref></s><s>Moreover, the cholesterol level may increase. <ref type="bibr" target="#b41">42,</ref><ref type="bibr" target="#b42">43</ref></s><s>Other nonhematologic AEs include constipation, diarrhea, and a folliculitis-like skin rash (supplemental Table <ref type="table" target="#tab_0">1</ref>). <ref type="bibr" target="#b16">17,</ref><ref type="bibr" target="#b40">41</ref></s><s>]<ref type="bibr" target="#b30">[31]</ref> Unfortunately, PAODs were also found to accumulate over time, and were recorded not only in patients in whom cardiovascular risk factors were present, but sometimes also in younger patients without risk factors concerning PAOD. <ref type="bibr" target="#b28">29,</ref><ref type="bibr" target="#b29">30,</ref><ref type="bibr" target="#b44">45,</ref><ref type="bibr" target="#b45">46</ref></s><s>31]<ref type="bibr" target="#b47">47</ref> In contrast, no increase in venous thromboembolic events has been reported for these patients.</s><s>A remarkable aspect is that VAEs were not reported in initial clinical trials testing nilotinib. <ref type="bibr" target="#b11">12,</ref><ref type="bibr" target="#b16">17</ref></s><s>onatinib is another novel TKI used to treat patients with drugresistant CML, including subclones expressing BCR/ABL T315I. <ref type="bibr" target="#b15">16,</ref><ref type="bibr" target="#b31">32</ref></s><s>irst clinical trials have shown that ponatinib is a highly potent agent and useful for the treatment of TKI-resistant CML. <ref type="bibr" target="#b15">16,</ref><ref type="bibr" target="#b31">32</ref></s><s>However, unfortunately, ponatinib triggers arterial hypertension as well as VAE development. <ref type="bibr" target="#b31">32</ref></s><s>Initially, these events were thought to accumulate in ponatinib-treated patients because of their prior exposure to nilotinib. <ref type="bibr" target="#b31">32,</ref><ref type="bibr" target="#b48">48,</ref><ref type="bibr" target="#b49">49</ref></s><s>More recent data suggest, however, that ponatinib can also induce VAEs in patients who had not received nilotinib. <ref type="bibr" target="#b39">40</ref></s><s>As a result, ponatinib was transiently removed from the market in the United States in 2013.</s><s>Remarkably, both arterial and venous thromboembolic events have been reported in ponatinibtreated patients. <ref type="bibr" target="#b31">32,</ref><ref type="bibr" target="#b39">40,</ref><ref type="bibr" target="#b49">49</ref></s><s>osutinib is another novel TKI that has been developed as a thirdline BCR/ABL1-targeting drug. <ref type="bibr" target="#b13">14,</ref><ref type="bibr" target="#b14">15,</ref><ref type="bibr" target="#b19">20,</ref><ref type="bibr" target="#b23">24</ref></s><s>Similar to nilotinib or dasatinib, bosutinib inhibits a number of BCR/ABL1 mutants and other kinase targets, but does not block BCR/ABL1 T315I. <ref type="bibr" target="#b19">20,</ref><ref type="bibr" target="#b23">24</ref></s><s>In contrast to other TKIs, bosutinib does not recognize KIT or PDGFR. <ref type="bibr" target="#b23">24</ref></s><s>he AE profile of bosutinib is also different compared with that of other TKIs.</s><s>Notably, bosutinib-treated patients may develop diarrhea and an exanthema. <ref type="bibr" target="#b14">15,</ref><ref type="bibr" target="#b19">20</ref></s><s>In addition, arterial hypertension, <ref type="bibr" target="#b50">50</ref> pleural effusions, and VAEs have been described in patients receiving bosutinib.</s><s>However, the frequency of VAEs is much lower compared with patients receiving nilotinib or ponatinib (supplemental Table <ref type="table" target="#tab_0">1</ref>). <ref type="bibr" target="#b50">50,</ref><ref type="bibr" target="#b51">51</ref></s><s>ported frequencies of VAEs in TKI-treated patients with CML So far, little is known about the exact incidence of VAEs in longterm TKI-treated patients with CML and about factors predisposing for VAE development.</s><s>From a clinical point of view, these are essential questions because many of these patients are candidates for long-term treatment or may be young and thus potentially transplantable, so that comorbidities must be kept to a minimum.</s><s>In initial phase 1 and 2 trials, VAEs were not captured, and therefore, VAE rates were not provided. <ref type="bibr" target="#b11">12,</ref><ref type="bibr" target="#b15">16,</ref><ref type="bibr" target="#b16">17</ref></s><s>Later, several centers recognized a potential relationship between drug intake and VAE development, and therefore started to record VAEs systematically.</s><s>In addition, several retrospective analyses were started, with the aim of exploring the frequency of VAEs in clinical trials.</s><s>However, the rates of VAEs in these surveys varied considerably.</s><s>5]<ref type="bibr" target="#b45">[46]</ref><ref type="bibr" target="#b47">[47]</ref><ref type="bibr" target="#b52">[52]</ref><ref type="bibr" target="#b53">[53]</ref><ref type="bibr" target="#b54">[54]</ref><ref type="bibr" target="#b55">[55]</ref><ref type="bibr" target="#b56">[56]</ref><ref type="bibr" target="#b57">[57]</ref><ref type="bibr">[58]</ref><ref type="bibr">[59]</ref> It was also found that the numbers (percentage) of patients developing VAEs increase over time (Table <ref type="table" target="#tab_0">1</ref>). <ref type="bibr" target="#b53">53,</ref><ref type="bibr" target="#b54">54</ref></s><s>By contrast, in retrospective analyses of larger clinical trials, the numbers of patients with documented VAEs remained low (,5%).</s><s>However, in first prospective analyses, the frequency of VAEs in these trials is again higher and increases over time.</s><s>There is also some indication that TKIs trigger VAE development in a dose-dependent manner.</s><s>Likewise, nilotinibtreated patients may be at higher risk of developing VAEs when receiving 2 3 400 mg per day compared with a lower dose (2 3 300 mg per day). <ref type="bibr" target="#b43">44,</ref><ref type="bibr" target="#b50">50</ref></s><s>he frequency of all VAEs in patients treated with ponatinib in the PACE trial was 8.9% after 11 months and 17.1% after 24 months (Table <ref type="table" target="#tab_0">1</ref>). <ref type="bibr" target="#b31">32,</ref><ref type="bibr" target="#b39">40,</ref><ref type="bibr" target="#b49">49</ref></s><s>As mentioned before, many of these patients had received nilotinib prior to their inclusion in the PACE trial.</s><s>However, VAEs were also recorded in patients who did not receive nilotinib prior to ponatinib. <ref type="bibr" target="#b39">40</ref></s><s>On the other hand, sequential treatment with nilotinib and ponatinib may be associated with a particularly high risk as recently documented in single case reports. <ref type="bibr" target="#b48">48</ref></s><s>lthough no long-term data from prospective trials are available, retrospective studies suggest that the frequency of VAEs in patients receiving imatinib is significantly lower than that observed with nilotinib or ponatinib. <ref type="bibr" target="#b53">53,</ref><ref type="bibr">60</ref></s><s>In 1 study, ,1% of all patients developed PAOD during imatinib. <ref type="bibr">60</ref></s><s>It is noteworthy that in contrast to nilotinib, imatinib is not increasing but may even decrease blood glucose levels. <ref type="bibr" target="#b59">61</ref></s><s>In addition, imatinib may counteract diabetes mellitus-associated atherosclerosis. <ref type="bibr" target="#b60">62</ref></s><s>Similar to imatinib, the frequency of VAEs in patients treated with dasatinib or bosutinib appears to be rather low.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Why did we initially overlook VAEs in our patients with CML?</head><p><s>A number of different factors may explain why we did initially overlook the VAE-triggering potential of nilotinib and ponatinib (Table <ref type="table" target="#tab_1">2</ref>).</s><s>This is an important issue and needs attention in the era of TKI therapy.</s><s>Specific factors and potential explanations are discussed in the supplemental Data.</s><s>The patients described in the above-listed investigations were in part from identical cohorts: patients reported in Aichberger et al <ref type="bibr" target="#b28">29</ref> were also included in the report by Le Coutre et al <ref type="bibr" target="#b29">30</ref> and data reported by Giles et al, <ref type="bibr" target="#b43">44</ref> Larsen et al, <ref type="bibr" target="#b52">52</ref> and Saglio et al <ref type="bibr" target="#b56">56</ref> were mostly from patients included in the ENESTnd trial.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Risk factors predisposing for the development of VAEs</head><p><s>NI, nilotinib; nr, not reported; PO, ponatinib.</s></p><p><s>]<ref type="bibr" target="#b63">[65]</ref> Interestingly, some of the risk factors predisposing for dasatiniband nilotinib-related AEs are the same. <ref type="bibr" target="#b63">65</ref></s><s>For example, age, arterial hypertension, and hypercholesterolemia are considered risk factors for both pleural effusion formation under dasatinib and PAOD development in patients receiving nilotinib (supplemental Table <ref type="table" target="#tab_1">2</ref>).</s></p><p><s>There are several other factors that have to be considered in these patients.</s><s>One such risk factor is the dose of the TKI.</s><s>Notably, clinically relevant AEs, including VAEs, appear to increase in frequency with higher TKI doses. <ref type="bibr" target="#b26">27,</ref><ref type="bibr" target="#b33">34,</ref><ref type="bibr" target="#b34">35,</ref><ref type="bibr" target="#b56">56,</ref><ref type="bibr" target="#b62">64</ref></s><s>In other words, it may well be that the rates of severe VAEs can be decreased substantially by lowering the TKI dose. <ref type="bibr" target="#b56">56</ref></s><s>In addition, the risk may decrease with shorter exposure times.</s><s>Another important point is previous therapy.</s><s>In fact, the risk may be higher in patients receiving certain TKIs in a sequential manner. <ref type="bibr" target="#b48">48</ref></s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Potential mechanisms underlying VAEs in TKI-treated patients</head><p><s>Several different factors may contribute to the development of VAEs in patients treated with nilotinib or ponatinib (supplemental Table <ref type="table">3</ref>). <ref type="bibr" target="#b53">53,</ref><ref type="bibr" target="#b63">65,</ref><ref type="bibr" target="#b64">66</ref></s><s>Because of the relatively short time interval between drug exposure and occurrence of VAEs, a direct effect of these TKIs on vascular and/or perivascular cells has been postulated. <ref type="bibr" target="#b53">53</ref></s><s>ndeed, nilotinib may exert direct proatherogenic and antiangiogenic effects on endothelial cells (supplemental Table <ref type="table">3</ref>). <ref type="bibr" target="#b53">53</ref></s><s>Whereas the proatherogenic effect may lead to arterial stenosis, the antiangiogenic effect of the drug may block repair mechanisms leading to recanalization and reperfusion once arterial stenosis occurred. <ref type="bibr" target="#b53">53</ref></s><s>It has also been described that nilotinib may cause vasospasms which may also be relevant and trigger PAOD development. <ref type="bibr" target="#b47">47</ref></s><s>n addition, nilotinib exerts metabolic effects, including an increase in cholesterol and fasting glucose levels (supplemental Table <ref type="table">3</ref>). <ref type="bibr" target="#b16">17,</ref><ref type="bibr" target="#b28">29,</ref><ref type="bibr" target="#b42">43,</ref><ref type="bibr" target="#b65">67,</ref><ref type="bibr" target="#b66">68</ref></s><s>Some patients even develop overt diabetes mellitus. <ref type="bibr" target="#b28">29,</ref><ref type="bibr" target="#b65">67</ref></s><s>All these drug effects are considered to act together to trigger atherosclerosis and VAE development. <ref type="bibr" target="#b51">51,</ref><ref type="bibr" target="#b65">67</ref></s><s>Recently, the proatherogenic effects of nilotinib have been confirmed by measuring the ankle brachial index (ABI) in patients with CML. <ref type="bibr" target="#b30">31</ref> So far, no data on ponatinib effects on vascular cells are available.</s><s>Preliminary data suggest that ponatinib also counteracts endothelial cell growth and survival (P.V. and E.H., unpublished observations from in vitro experiments using human endothelial cells).</s><s>So far, little is known about molecular targets responsible for nilotinib and ponatinib effects on vascular endothelial cells. <ref type="bibr" target="#b53">53</ref></s><s>everal of these target antigens are major angiogenic receptors, like KDR (a known ponatinib-target) or TEK/Tie-2. <ref type="bibr" target="#b53">53</ref></s><s>The impact of these targets in VAE development is under investigation.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Management of VAEs in patients with CML</head><p><s>In patients developing VAEs during treatment with nilotinib or ponatinib, management depends on the overall situation in each case.</s><s>In patients with low-grade (grade I and II) PAOD, optimal therapy of PAOD and the elimination of all risk factors (smoking, obesity, diabetes mellitus, arterial hypertension, hypercholesterolemia) may lead to a stabilization of the condition, so that treatment can be continued (which is important as some of these patients may have no other therapeutic options; eg, those with BCR/ABL1 T315I).</s><s>For these patients, a thorough follow-up regarding cardiovascular and metabolic parameters (including vascular ultrasound investigations, ABI, cholesterol and fasting glucose levels, HbA1c) and PAOD-related risk factors (age, obesity, arterial blood pressure, smoking habits) is recommended. <ref type="bibr" target="#b30">31</ref></s><s>In addition, prophylactic treatment with aspirin should be considered.</s><s>Additional comedication may also be required, depending on risk factors and comorbidities.</s><s>These patients may receive antidiabetic and/or cholesterol-lowering drugs.</s></p><p><s>In patients with high-grade PAOD (grade III or IV) the situation is more difficult to manage.</s><s>Some of these patients may still need to be treated with nilotinib or ponatinib based on the biology (mutation status) of their CML.</s><s>In other patients, the drug should be discontinued or replaced by another TKI.</s><s>In select cases with stable complete molecular response (CMR), discontinuation of TKI therapy may be considered. <ref type="bibr" target="#b67">69</ref></s><s>For all other patients, a general recommendation is to switch to another TKI if possible.</s><s>PAOD requiring interventional revascularization procedures, central (cerebral) ischemia, and myocardial infarction is an additional indication to switch to another TKI.</s><s>In all of these patients, platelet aggregation inhibitors or anticoagulation should be considered following generally accepted guidelines.</s><s>In these patients, it is also essential to eliminate all risk factors and to treat hyperlipidemia, diabetes mellitus, and arterial hypertension early and as effectively as possible (supplemental Table <ref type="table">4</ref>).</s><s>An unresolved question is whether a slight elevation in the fasting glucose level, which is quite frequently seen in nilotinib-treated patients, should already lead to early intervention with antidiabetic therapy.</s><s>At least repeated testing of glucose and HbA1c, and an oral glucose tolerance test (OGTT), seems justified; when the fasting glucose level permanently increases to .125 mg/dL or the OGTT is clearly pathologic, antidiabetic treatment should be considered.</s><s>Only a very few drugs are known to promote atherosclerosis, and only a very few drugs used to treat hematologic neoplasms may promote VAE development.</s></p><p><s>The initial clinical trials were not powered for the detection of VAEs.</s></p><p><s>Most clinical trials excluded patients with severe cardiac and/or metabolic comorbidities.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Secondary</head><p><s>Latency period of several months to years before VAEs develop during TKI therapy.</s></p><p><s>CML centers and local experts are not trained to detect and to manage VAEs.</s></p><p><s>VAEs are not "oncologic": therefore, VAE patients were neither reported nor referred back to the oncologist by the practitioners.</s><s>Also, the patients did not report for the same reason and because of the general incidence.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Other</head><p><s>Major papers published in top journals did not report on VAE development.</s></p><p><s>Initially, nilotinib was reported as an extremely safe TKI without side effects.</s></p><p><s>In major and special meetings, TKIs were long reported as safe without an impact on development of vascular diseases.</s></p><p><s>Clinically silent vascular events in diabetic patients may be overlooked.</s></p><p><s>Sudden death before a cerebral or cardiac VAE was detected.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>How to prevent the development of VAEs in TKI-treated patients</head><p><s>Based on the severity of VAEs, the relatively good prognosis of CML patients even in the second-and third-line setting, and the impact of VAEs on overall morbidity and transplant eligibility, it is of utmost importance to avoid VAEs in all CML patients, regardless of age and other factors.</s><s>A first important step in prevention is patient selection for second-and third-line TKIs.</s><s>Such TKIs should be selected not only on the basis of disease-related parameters such as BCR/ABL1 mutations, but also based on patientrelated variables, including comorbidities and overt risk factors for AE development.</s><s>Indeed, more and more guidelines and treatment algorithms take patient-related factors into account, thereby fulfilling the criteria of personalized medicine. <ref type="bibr" target="#b4">5,</ref><ref type="bibr" target="#b10">11</ref></s><s>ased on the frequent detection of risk factors for PAOD development in the general population (adults) in the western world, it is important to determine the individual risk in each case using validated scores, such as the European Society of Cardiology (ESC) score.</s><s>This score should indeed be applied in order to select optimal and safe TKIs for all patients with CML.</s><s>Patients in whom multiple risk factors or/and a high ESC score are found should not be exposed to nilotinib or ponatinib if other TKIs can be prescribed.</s><s>However, even low-risk patients according to the ESC score may develop VAEs during TKI therapy (P.V., personal observation: ESC scoring of CML patients treated at the Medical University of Vienna).</s><s>Another unfortunate aspect is that several risk factors for PAOD development are also independent risk factors for the development of pleural effusions during dasatinib therapy (supplemental Table <ref type="table" target="#tab_1">2</ref>). <ref type="bibr" target="#b61">63,</ref><ref type="bibr" target="#b62">64</ref></s><s>Especially in elderly patients, neither nilotinib nor dasatinib may be an optimal TKI.</s><s>Whether bosutinib may be a better choice for these patients remains to be determined in clinical trials.</s><s>In contrast, ponatinib should not be considered as an alternative drug in these patients, unless leukemic cells express BCR/ABL1 T315I.</s><s>In each case, the potential benefit of ponatinib has to be balanced against the potential AE risk.</s><s>Several other strategies may keep the risk of severe VAEs in TKI-treated CML patients to a minimum.</s><s>These strategies are described in the supplemental Data.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Concluding remarks and future perspectives</head><p><s>Vascular safety has become an emerging challenge in the treatment of CML patients with second-and third-generation BCR/ABL1 TKIs.</s><s>Whereas the vascular safety of imatinib is well documented, exposure to nilotinib and ponatinib is associated with an increased rate of arterial occlusive events.</s><s>Therefore, it is of great importance to consider the overall risk profile before starting therapy, and to include comorbidities and risk factors for AOD development in novel treatment algorithms.</s><s>It is also important to monitor metabolic and cardiovascular parameters in these patients and to reduce the vascular risk by optimal patient selection, comedication, and early intervention if necessary.</s><s>Although the mechanisms of druginduced vascular damage are not well understood, direct proatherogenic and growth-inhibitory effects on endothelial cells as well as metabolic drug effects seem to contribute.</s><s>Currently, novel TKIs that spare critical vascular targets but retain full anti-CML activity are developed, with the hope of improving safety in longterm treated patients.</s><s>Alternative options might be to discontinue or to "switch back" to less toxic TKIs once a stable deep response has been reached.</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Table 1 .</head><label>1</label><figDesc><div><p><s>Reported numbers of CML patients developing VAEs and peripheral occlusive VAEs (PAOD) during treatment with nilotinib or ponatinib</s></p></div></figDesc><table><row><cell>No. of</cell><cell></cell><cell></cell><cell></cell><cell>Observation</cell><cell></cell></row><row><cell>patients (n)</cell><cell>TKI</cell><cell>VAE %</cell><cell>PAOD %</cell><cell>time, mo</cell><cell>Reference</cell></row><row><cell>24</cell><cell>NI</cell><cell>25.0</cell><cell>16.5</cell><cell>24</cell><cell>29</cell></row><row><cell>179</cell><cell>NI</cell><cell>nr</cell><cell>6.2</cell><cell>nr</cell><cell>30</cell></row><row><cell>233</cell><cell>NI</cell><cell>2.0</cell><cell>1.3</cell><cell>nr</cell><cell>47</cell></row><row><cell>556</cell><cell>NI</cell><cell>4.9</cell><cell>1.3</cell><cell>36</cell><cell>52</cell></row><row><cell>54</cell><cell>NI</cell><cell>nr</cell><cell>13.0</cell><cell>26.4</cell><cell>55</cell></row><row><cell>66</cell><cell>NI</cell><cell>nr</cell><cell>6.0</cell><cell>nr</cell><cell>31</cell></row><row><cell>75</cell><cell>NI</cell><cell>9.8</cell><cell>8.0</cell><cell>24</cell><cell>54</cell></row><row><cell></cell><cell></cell><cell>19.3</cell><cell>nr</cell><cell>36</cell><cell></cell></row><row><cell></cell><cell></cell><cell>27.7</cell><cell>nr</cell><cell>48</cell><cell></cell></row><row><cell>34</cell><cell>NI</cell><cell>29.4</cell><cell>20.6</cell><cell>24</cell><cell>53</cell></row><row><cell></cell><cell></cell><cell>38.9</cell><cell>33.3</cell><cell>36</cell><cell></cell></row><row><cell>563</cell><cell>NI</cell><cell>7.0</cell><cell>1.2</cell><cell>48</cell><cell>56</cell></row><row><cell>556</cell><cell>NI</cell><cell>nr</cell><cell>1.3</cell><cell>36</cell><cell>44</cell></row><row><cell>27</cell><cell>NI</cell><cell>nr</cell><cell>14.8</cell><cell>24</cell><cell>45</cell></row><row><cell>31</cell><cell>NI</cell><cell>nr</cell><cell>9.7</cell><cell>31</cell><cell>57</cell></row><row><cell>55</cell><cell>NI</cell><cell>11.0</cell><cell>1.8</cell><cell>28</cell><cell>58</cell></row><row><cell>98</cell><cell>NI</cell><cell>nr</cell><cell>3.1</cell><cell>31</cell><cell>59</cell></row><row><cell>449</cell><cell>PO</cell><cell>8.9</cell><cell>4.9</cell><cell>11</cell><cell>32</cell></row><row><cell></cell><cell></cell><cell>17.1</cell><cell>11.8</cell><cell>24</cell><cell></cell></row></table><note><p><s>TKI-related side effects may preferentially develop in patients who have preexisting risk factors.</s><s>Likewise, in most CML patients treated with nilotinib or ponatinib in whom severe recurrent VAEs were</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>Table 2 .</head><label>2</label><figDesc><div><p><s>Reasons for underreporting of VAEs in CML patients treated with BCR/ABL1 TKIs Reasons Primary Relatively high incidence of atherosclerosis and VAEs worldwide.</s><s>Relatively low patient numbers per center participating in clinical trials.</s></p></div></figDesc><table /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_2"><head></head><label></label><figDesc><div><p><s>58. Gora-Tybor J, Medras E, Calbecka M, et al.</s><s>Real-life comparison of severe vascular events and other non-hematological complications in CML patients treated with second line nilotinib or dasatinib.</s><s>Blood.</s><s>2013;122(21).</s><s>Abstract 1491.</s></p></div></figDesc><table /><note><p><s>59. Jeon YW, Lee SE, Choi SY, et al.</s><s>Peripheral arterial occlusive disease (PAOD) in chronic phase chronic myeloid leukemia patients treated with nilotinib.</s><s>Blood.</s><s>2013;122(21).</s><s>Abstract 4018.</s><s>60.</s><s>Hehlmann R, Lauseker M, Schreiber A, et al.</s><s>Adverse events (AE) under imatinib treatment over 10 years: results from 1501 patients of the</s></p></note></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">Downloaded from http://ashpublications.org/blood/article-pdf/125/6/901/1386778/901.pdf by guest on 17 May 2022</note>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Acknowledgments</head><p><s>This work was supported by Austrian Science Fund (FWF) project SFB F4704-B20.</s></p></div>
			</div>

			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Authorship</head><p><s>Contribution: P.V., E.H., G.-H.S., D.W., D.R., and P.l.C. participated in vital discussions, drafted parts of the article, prepared the tables, critically read the document, and approved the final version of the manuscript.</s></p><p><s>Conflict-of-interest disclosure: P.V. has a consultancy with Novartis, received a research grant from Novartis, and received honoraria from Novartis, Bristol-Myers Squibb (BMS), Pfizer, and Ariad.</s><s>G.-H.S. received honoraria from Amgen, Astra Zeneca, Boehringer Ingelheim, BMS, Daiichi Sankyo, Elli Lilly, Medtronic, Menarini, Merck, Merck Sharp &amp; Dohme, Novo-Nordisk, Novartis, Pfizer, Sanofi, Sanofi-Aventis, Servier, and Takeda.</s><s>D.W. received honoraria from BMS, Novartis, and Pfizer, and research support from Novartis.</s><s>D.R. received honoraria from BMS, Novartis, Pfizer, Ariad, and Teva.</s><s>P.l.C. received a research grant from Novartis and received honoraria from Novartis, BMS, Pfizer, and Ariad.</s><s>E.H. declares no competing financial interests.</s></p><p><s>Correspondence: Peter Valent, Department of Internal Medicine I, Division of Hematology &amp; Hemostaseology and Ludwig Boltzmann Cluster Oncology, Medical University of Vienna, Waehringer Guertel 18-20, A-1090 Vienna, Austria; e-mail: peter.valent@</s><s>meduniwien.ac.at.</s></p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">The biology of chronic myeloid leukemia</title>
		<author>
			<persName><forename type="first">S</forename><surname>Faderl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Talpaz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Estrov</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>O'brien</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Kurzrock</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">M</forename><surname>Kantarjian</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">341</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="164" to="172" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Chronic myeloid leukaemia as a model of disease evolution in human cancer</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">V</forename><surname>Melo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Barnes</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Rev Cancer</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="441" to="453" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Perspectives on the development of a molecularly targeted agent</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">J</forename><surname>Druker</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Cell</title>
		<imprint>
			<biblScope unit="volume">1</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="31" to="36" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">J</forename><surname>Druker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Guilhot</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">G</forename><surname>O'brien</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">IRIS Investigators</title>
				<imprint>
			<date type="published" when="2006">2006</date>
			<biblScope unit="volume">355</biblScope>
			<biblScope unit="page" from="2408" to="2417" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Standard treatment of Ph1 CML in 2010: how, when and where not to use what BCR/ ABL1 kinase inhibitor?</title>
		<author>
			<persName><forename type="first">P</forename><surname>Valent</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Clin Invest</title>
		<imprint>
			<biblScope unit="volume">40</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page" from="918" to="931" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia</title>
		<author>
			<persName><forename type="first">T</forename><surname>O'hare</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">A</forename><surname>Eide</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">W</forename><surname>Deininger</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">110</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page" from="2242" to="2249" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Mechanisms of primary and secondary resistance to imatinib in chronic myeloid leukemia</title>
		<author>
			<persName><forename type="first">A</forename><surname>Quint Ás-Cardama</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">M</forename><surname>Kantarjian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">E</forename><surname>Cortes</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Contr</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="122" to="131" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">New tyrosine kinase inhibitors in chronic myeloid leukemia</title>
		<author>
			<persName><forename type="first">G</forename><surname>Martinelli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Soverini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Rosti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Cilloni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Baccarani</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Haematologica</title>
		<imprint>
			<biblScope unit="volume">90</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="534" to="541" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Resistance to imatinib: mutations and beyond</title>
		<author>
			<persName><forename type="first">La</forename><surname>Ros Ée</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Deininger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">W</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Semin Hematol</title>
		<imprint>
			<biblScope unit="volume">47</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="335" to="343" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Monitoring response to tyrosine kinase inhibitor therapy, mutational analysis, and new treatment options in chronic myelogenous leukemia</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Radich</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Natl Compr Canc Netw</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="663" to="666" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
	<note>suppl</note>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Resistance to tyrosine kinase inhibition therapy for chronic myelogenous leukemia: a clinical perspective and emerging treatment options</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">J</forename><surname>Jabbour</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">E</forename><surname>Cortes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">M</forename><surname>Kantarjian</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Lymphoma Myeloma Leuk</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="515" to="529" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL</title>
		<author>
			<persName><forename type="first">H</forename><surname>Kantarjian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Giles</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Wunderle</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">354</biblScope>
			<biblScope unit="issue">24</biblScope>
			<biblScope unit="page" from="2542" to="2551" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Dasatinib in imatinib-resistant Philadelphia chromosomepositive leukemias</title>
		<author>
			<persName><forename type="first">M</forename><surname>Talpaz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">P</forename><surname>Shah</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Kantarjian</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">354</biblScope>
			<biblScope unit="issue">24</biblScope>
			<biblScope unit="page" from="2531" to="2541" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">E</forename><surname>Cortes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">M</forename><surname>Kantarjian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">H</forename><surname>Br Ümmendorf</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">118</biblScope>
			<biblScope unit="issue">17</biblScope>
			<biblScope unit="page" from="4567" to="4576" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/ or nilotinib therapy failure</title>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">J</forename><surname>Khoury</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">E</forename><surname>Cortes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">M</forename><surname>Kantarjian</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">119</biblScope>
			<biblScope unit="issue">15</biblScope>
			<biblScope unit="page" from="3403" to="3412" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Ponatinib in refractory Philadelphia chromosome-positive leukemias</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">E</forename><surname>Cortes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Kantarjian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">P</forename><surname>Shah</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">367</biblScope>
			<biblScope unit="issue">22</biblScope>
			<biblScope unit="page" from="2075" to="2088" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">ENESTnd Investigators. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia</title>
		<author>
			<persName><forename type="first">G</forename><surname>Saglio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">W</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Issaragrisil</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">362</biblScope>
			<biblScope unit="issue">24</biblScope>
			<biblScope unit="page" from="2251" to="2259" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia</title>
		<author>
			<persName><forename type="first">H</forename><surname>Kantarjian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">P</forename><surname>Shah</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Hochhaus</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">362</biblScope>
			<biblScope unit="issue">24</biblScope>
			<biblScope unit="page" from="2260" to="2270" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Nilotinib is superior to imatinib as first-line therapy of chronic myeloid leukemia: the ENESTnd study</title>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">J</forename><surname>Giles</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Rosti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Beris</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Expert Rev Hematol</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="665" to="673" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">E</forename><surname>Cortes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">W</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">M</forename><surname>Kantarjian</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">30</biblScope>
			<biblScope unit="issue">28</biblScope>
			<biblScope unit="page" from="3486" to="3492" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets</title>
		<author>
			<persName><forename type="first">U</forename><surname>Rix</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Hantschel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">110</biblScope>
			<biblScope unit="issue">12</biblScope>
			<biblScope unit="page" from="4055" to="4063" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors</title>
		<author>
			<persName><forename type="first">M</forename><surname>Bantscheff</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Eberhard</forename><forename type="middle">D</forename><surname>Abraham</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Biotechnol</title>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<biblScope unit="issue">9</biblScope>
			<biblScope unit="page" from="1035" to="1044" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib</title>
		<author>
			<persName><forename type="first">O</forename><surname>Hantschel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Rix</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Superti-Furga</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Leuk Lymphoma</title>
		<imprint>
			<biblScope unit="volume">49</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="615" to="619" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells</title>
		<author>
			<persName><forename type="first">Remsing</forename><surname>Rix</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">L</forename><surname>Rix</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Colinge</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Leukemia</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="477" to="485" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Extended kinase profile and properties of the protein kinase inhibitor nilotinib</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">W</forename><surname>Manley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Drueckes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Fendrich</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Biochim Biophys Acta</title>
		<imprint>
			<biblScope unit="volume">1804</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="445" to="453" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure</title>
		<author>
			<persName><forename type="first">A</forename><surname>Quint Ás-Cardama</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Kantarjian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>O'brien</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<biblScope unit="issue">25</biblScope>
			<biblScope unit="page" from="3908" to="3914" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">Immunosuppression and atypical infections in CML patients treated with dasatinib at 140 mg daily</title>
		<author>
			<persName><forename type="first">C</forename><surname>Sillaber</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Herrmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Bennett</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Clin Invest</title>
		<imprint>
			<biblScope unit="volume">39</biblScope>
			<biblScope unit="issue">12</biblScope>
			<biblScope unit="page" from="1098" to="1109" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">Extensive pleural and pericardial effusion in chronic myeloid leukemia during treatment with dasatinib at 100 mg or 50 mg daily</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">T</forename><surname>Krauth</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Herndlhofer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">T</forename><surname>Schmook</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Mitterbauer-Hohendanner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Valent</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Haematologica</title>
		<imprint>
			<biblScope unit="volume">96</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="163" to="166" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">J</forename><surname>Aichberger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Herndlhofer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">H</forename><surname>Schernthaner</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Hematol</title>
		<imprint>
			<biblScope unit="volume">86</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page" from="533" to="539" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">Severe peripheral arterial disease during nilotinib therapy</title>
		<author>
			<persName><forename type="first">Le</forename><surname>Coutre</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Rea</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Abruzzese</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Natl Cancer Inst</title>
		<imprint>
			<biblScope unit="volume">103</biblScope>
			<biblScope unit="issue">17</biblScope>
			<biblScope unit="page" from="1347" to="1348" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">D</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Rea</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Schwarz</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Leukemia</title>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="1316" to="1321" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">E</forename><surname>Cortes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">W</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Pinilla-Ibarz</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">PACE Investigators</title>
				<imprint>
			<date type="published" when="2013">2013</date>
			<biblScope unit="volume">369</biblScope>
			<biblScope unit="page" from="1783" to="1796" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">Reversible lymph node follicular hyperplasia associated with dasatinib treatment of chronic myeloid leukemia in chronic phase</title>
		<author>
			<persName><forename type="first">C</forename><surname>Roux</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">E</forename><surname>Nicolini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Rea</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">122</biblScope>
			<biblScope unit="issue">17</biblScope>
			<biblScope unit="page" from="3082" to="3084" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia</title>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">P</forename><surname>Shah</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">M</forename><surname>Kantarjian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">W</forename><surname>Kim</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="issue">19</biblScope>
			<biblScope unit="page" from="3204" to="3212" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main">Dasatinib dosing strategies in Philadelphia chromosome-positive leukemia</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">F</forename><surname>Wong</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Oncol Pharm Pract</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="17" to="27" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main">Pleural and pericardial effusions in chronic myeloid leukemia patients receiving low-dose dasatinib therapy</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">E</forename><surname>Eskazan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Soysal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Ongoren</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Gulturk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Ferhanoglu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Aydin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">e15, author reply</title>
				<imprint>
			<date type="published" when="2011">2011</date>
			<biblScope unit="volume">96</biblScope>
			<biblScope unit="page" from="e16" to="e17" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main">Reversible severe pulmonary hypertension secondary to dasatinib in a patient with chronic myeloid leukemia</title>
		<author>
			<persName><forename type="first">W</forename><surname>Rasheed</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Flaim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">F</forename><surname>Seymour</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Leuk Res</title>
		<imprint>
			<biblScope unit="volume">33</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="861" to="864" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main">Pulmonary arterial hypertension in patients treated by dasatinib</title>
		<author>
			<persName><forename type="first">D</forename><surname>Montani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Bergot</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Circulation</title>
		<imprint>
			<biblScope unit="volume">125</biblScope>
			<biblScope unit="issue">17</biblScope>
			<biblScope unit="page" from="2128" to="2137" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main">Pulmonary arterial hypertension caused by treatment with dasatinib for chronic myeloid leukemia -critical alert</title>
		<author>
			<persName><forename type="first">M</forename><surname>Sano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Saotome</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Urushida</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Intern Med</title>
		<imprint>
			<biblScope unit="volume">51</biblScope>
			<biblScope unit="issue">17</biblScope>
			<biblScope unit="page" from="2337" to="2340" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title level="a" type="main">Efficacy and safety of ponatinib following failure of dasatinib in patients with chronic phase chronic myeloid leukemia (CP-CML) in the PACE trial</title>
		<author>
			<persName><forename type="first">A</forename><surname>Hochhaus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">E</forename><surname>Cortes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">W</forename><surname>Kim</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">122</biblScope>
			<biblScope unit="issue">12</biblScope>
			<date type="published" when="1498">2013. 1498</date>
		</imprint>
	</monogr>
	<note>Abstract</note>
</biblStruct>

<biblStruct xml:id="b40">
	<analytic>
		<title level="a" type="main">Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia</title>
		<author>
			<persName><forename type="first">P</forename><surname>Le Coutre</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><forename type="middle">G</forename><surname>Ottmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Giles</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">111</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="1834" to="1839" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b41">
	<analytic>
		<title level="a" type="main">Nilotinib therapy does not induce consistent modifications of cholesterol metabolism resulting in clinical consequences</title>
		<author>
			<persName><forename type="first">M</forename><surname>Breccia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Loglisci</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Cannella</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Leuk Res</title>
		<imprint>
			<biblScope unit="volume">35</biblScope>
			<biblScope unit="issue">11</biblScope>
			<biblScope unit="page" from="e215" to="e216" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b42">
	<analytic>
		<title level="a" type="main">Early onset hypercholesterolemia induced by the 2nd-generation tyrosine kinase inhibitor nilotinib in patients with chronic phase-chronic myeloid leukemia</title>
		<author>
			<persName><forename type="first">D</forename><surname>Rea</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Mirault</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Cluzeau</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Haematologica</title>
		<imprint>
			<biblScope unit="volume">99</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page" from="1197" to="1203" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b43">
	<analytic>
		<title level="a" type="main">Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or nontyrosine kinase therapy: a retrospective cohort analysis</title>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">J</forename><surname>Giles</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Mauro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Hong</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Leukemia</title>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="1310" to="1315" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b44">
	<analytic>
		<title level="a" type="main">Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in chronic myeloid leukemia: a single institution study</title>
		<author>
			<persName><forename type="first">L</forename><surname>Levato</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Cantaffa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">G</forename><surname>Kropp</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Magro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Piro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Molica</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Haematol</title>
		<imprint>
			<biblScope unit="volume">90</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="531" to="532" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b45">
	<monogr>
		<title level="m" type="main">Rapid onset of peripheral artery disease in a chronic myeloid leukemia patient without prior arterial disorder: direct relationship with nilotinib exposure and clinical outcome</title>
		<author>
			<persName><forename type="first">T</forename><surname>Mirault</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Rea</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Azarine</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Messas</surname></persName>
		</author>
		<imprint/>
	</monogr>
	<note>published online ahead of print May 3, 2014</note>
</biblStruct>

<biblStruct xml:id="b46">
	<analytic>
		<title/>
	</analytic>
	<monogr>
		<title level="j">Eur J Haematol</title>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b47">
	<analytic>
		<title level="a" type="main">Nilotinib-associated vascular events</title>
		<author>
			<persName><forename type="first">A</forename><surname>Quint Ás-Cardama</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Kantarjian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Cortes</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Lymphoma Myeloma Leuk</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="337" to="340" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b48">
	<analytic>
		<title level="a" type="main">Fatal progressive cerebral ischemia in CML under third-line treatment with ponatinib</title>
		<author>
			<persName><forename type="first">K</forename><surname>Mayer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">H</forename><surname>Gielen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Willinek</surname></persName>
		</author>
		<author>
			<persName><surname>Mc</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Wolf</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Leukemia</title>
		<imprint>
			<biblScope unit="volume">28</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="976" to="977" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b49">
	<analytic>
		<title level="a" type="main">Efficacy and safety of ponatinib following failure of nilotinib in patients with chronic phase chronic myeloid leukemia (CP-CML) in the PACE trial</title>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">M</forename><surname>Kantarjian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">E</forename><surname>Cortes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">W</forename><surname>Kim</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">122</biblScope>
			<biblScope unit="issue">12</biblScope>
			<date type="published" when="2013">2013. 2738</date>
		</imprint>
	</monogr>
	<note>Abstract</note>
</biblStruct>

<biblStruct xml:id="b50">
	<analytic>
		<title level="a" type="main">Longterm evaluation of vascular toxicity in patients with Ph1 leukemias treated with bosutinib</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">E</forename><surname>Cortes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">M</forename><surname>Kantarjian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">J</forename><surname>Khoury</surname></persName>
		</author>
		<idno>5s. ASCO abstract 7060</idno>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">32</biblScope>
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b51">
	<analytic>
		<title level="a" type="main">Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia</title>
		<author>
			<persName><forename type="first">C</forename><surname>Gambacorti-Passerini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">E</forename><surname>Cortes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">H</forename><surname>Lipton</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Hematol</title>
		<imprint>
			<biblScope unit="volume">89</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page" from="947" to="953" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b52">
	<analytic>
		<title level="a" type="main">Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Larson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Hochhaus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">P</forename><surname>Hughes</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Leukemia</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page" from="2197" to="2203" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b53">
	<analytic>
		<title level="a" type="main">Nilotinib exerts direct pro-atherogenic and anti-angiogenic effects on vascular endothelial cells: a potential explanation for drug-iduced vasculopathy in CML</title>
		<author>
			<persName><forename type="first">E</forename><surname>Hadzijusufovic</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Albrecht-Schgoer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Huber</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">122</biblScope>
			<biblScope unit="issue">12</biblScope>
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
	<note>Abstract 257</note>
</biblStruct>

<biblStruct xml:id="b54">
	<analytic>
		<title level="a" type="main">Identification of patients (pts) with chronic myeloid leukemia (CML) at high risk of artery occlusive events (AOE) during treatment with the 2nd generation tyrosine kinase inhibitor (TKI) nilotinib using risk stratification for cardiovascular diseases (CVD)</title>
		<author>
			<persName><forename type="first">D</forename><surname>Rea</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Mirault</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Raffoux</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">122</biblScope>
			<biblScope unit="issue">12</biblScope>
			<date type="published" when="2013">2013. 2726</date>
		</imprint>
	</monogr>
	<note>Abstract</note>
</biblStruct>

<biblStruct xml:id="b55">
	<analytic>
		<title level="a" type="main">Analysis of clinical arterial and metabolic parameters in chronic phase cml patients on nilotinib in a single center cohort</title>
		<author>
			<persName><forename type="first">H</forename><surname>Labussi Ère-Wallet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Guillermin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Etienne</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">120</biblScope>
			<biblScope unit="issue">21</biblScope>
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
	<note>Abstract 3756</note>
</biblStruct>

<biblStruct xml:id="b56">
	<analytic>
		<title level="a" type="main">ENESTnd Update: nilotinib (NIL) vs imatinib (IM) in patients (PTS) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) and the impact of early molecular response (EMR) and sokal risk at diagnosis on long-term outcomes</title>
		<author>
			<persName><forename type="first">G</forename><surname>Saglio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Hochhaus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">P</forename><surname>Hughes</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">122</biblScope>
			<biblScope unit="issue">21</biblScope>
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
	<note>Abstract 92</note>
</biblStruct>

<biblStruct xml:id="b57">
	<analytic>
		<title level="a" type="main">Hypercholesterolemia in imatinib intolerant/ resistant CML-CP patients treated with nilotinib: a retrospective analysis</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">K</forename><surname>Hiwase</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">T</forename><surname>Yeung</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Carne</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">122</biblScope>
			<biblScope unit="issue">21</biblScope>
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
	<note>Abstract 1503</note>
</biblStruct>

<biblStruct xml:id="b58">
	<analytic>
		<title level="a" type="main">Abstract 4012</title>
		<idno>randomized CML-study IV</idno>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">122</biblScope>
			<biblScope unit="issue">12</biblScope>
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b59">
	<analytic>
		<title level="a" type="main">Imatinib mesylate may improve fasting blood glucose in diabetic Ph1 chronic myelogenous leukemia patients responsive to treatment</title>
		<author>
			<persName><forename type="first">M</forename><surname>Breccia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Muscaritoli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Aversa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Mandelli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Alimena</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="issue">22</biblScope>
			<biblScope unit="page" from="4653" to="4655" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b60">
	<analytic>
		<title level="a" type="main">Imatinib attenuates diabetes-associated atherosclerosis</title>
		<author>
			<persName><forename type="first">M</forename><surname>Lassila</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">J</forename><surname>Allen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Cao</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arterioscler Thromb Vasc Biol</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="935" to="942" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b61">
	<analytic>
		<title level="a" type="main">Charlson comorbidity index and adult comorbidity evaluation-27 scores might predict treatment compliance and development of pleural effusions in elderly patients with chronic myeloid leukemia treated with second-line dasatinib</title>
		<author>
			<persName><forename type="first">M</forename><surname>Breccia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Latagliata</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Stagno</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Haematologica</title>
		<imprint>
			<biblScope unit="volume">96</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page" from="1457" to="1461" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b62">
	<analytic>
		<title level="a" type="main">Pleural effusions in patients with chronic myeloid leukaemia treated with dasatinib may have an immune-mediated pathogenesis</title>
		<author>
			<persName><forename type="first">H</forename><surname>De Lavallade</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Punnialingam</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Milojkovic</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br J Haematol</title>
		<imprint>
			<biblScope unit="volume">141</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="745" to="747" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b63">
	<analytic>
		<title level="a" type="main">Severe adverse events associated with the use of second-line BCR/ABL tyrosine kinase inhibitors: preferential occurrence in patients with comorbidities</title>
		<author>
			<persName><forename type="first">P</forename><surname>Valent</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Haematologica</title>
		<imprint>
			<biblScope unit="volume">96</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page" from="1395" to="1397" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b64">
	<analytic>
		<title level="a" type="main">Atherothrombotic risk and TKI treatment In chronic myeloid leukemia patients: a role for genetic predisposition and pro-inflammatory/pro-oxidative status?</title>
		<author>
			<persName><forename type="first">L</forename><surname>Aprile</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Puccetti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Galimberti</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">122</biblScope>
			<biblScope unit="issue">12</biblScope>
			<date type="published" when="1482">2013. 1482</date>
		</imprint>
	</monogr>
	<note>Abstract</note>
</biblStruct>

<biblStruct xml:id="b65">
	<analytic>
		<title level="a" type="main">Mechanism of impaired glucose metabolism during nilotinib therapy in patients with chronic myelogenous leukemia</title>
		<author>
			<persName><forename type="first">Z</forename><surname>Racil</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Razga</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Drapalova</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Haematologica</title>
		<imprint>
			<biblScope unit="volume">98</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page" from="e124" to="e126" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b66">
	<analytic>
		<title level="a" type="main">Impaired fasting glucose level as metabolic side effect of nilotinib in non-diabetic chronic myeloid leukemia patients resistant to imatinib</title>
		<author>
			<persName><forename type="first">M</forename><surname>Breccia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Muscaritoli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Gentilini</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Leuk Res</title>
		<imprint>
			<biblScope unit="volume">31</biblScope>
			<biblScope unit="issue">12</biblScope>
			<biblScope unit="page" from="1770" to="1772" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b67">
	<analytic>
		<title level="a" type="main">Intergroupe Franc ¸ais des Leuc émies My éloïdes Chroniques. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial</title>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">X</forename><surname>Mahon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Guilhot</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet Oncol</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="issue">11</biblScope>
			<biblScope unit="page" from="1029" to="1035" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
